Abstract 215P
Background
Introduction: About 2-3% of all cancers are renal cell carcinoma (RCC). Nephrectomy is the main treatment. The decision among radical and partial nephrectomy often relies on the tumor size diagnosed by CT scan. It is thus justified to investigate the variation between the radiologic and pathologic size of the tumor and its implications on the management of renal cell carcinoma. Aim: To assess the variation between the radiologic tumor size (RTS) of localized renal cell cancer as measured by Computed tomography (CT) preoperatively and the pathologic tumor size (PTS) as determined from surgical specimen postoperatively.
Methods
The records of 240 patients who underwent nephrectomy due to RCC were taken from the Urology Department of Trivandrum Medical College, Kerala, India. The difference of means for the tumor size on Computed Tomography (CT) scan/ the radiologic tumor size (RTS) and pathologic tumor size (PTS) was calculated using paired T test; the difference was also categorised in terms of sex, type of RCC, type of nephrectomy and T staging. A p value of < 0.05 was considered statistically significant.
Results
The mean age of cases included was 54.82 years (22-78 years) (SD 10.991). The mean RTS was larger than PTS (5.22 ± 2.15 vs. 4.98 ± 2.04 cm, p = <0.001) with a discrepancy of 0.24 cm. The difference among means was found significant for both males and females; significant among clear cell RCC and non - clear cell RCC; and significant for radical neohrectomy but not for partial nephrectomy. Overall 41 of the 240 tumors were down-staged while another 5 up-staged.
Table: 215P Characteristics of the 240 patients with localized renal cell carcinoma
Number of patients | 240 | |
Average age (years) | 54.82 (SD 10.991) | |
Gender- | ||
Male | 159 (66.2%) | |
Female | 81 (33.8%) | |
Histopathologic type- | ||
Clear Cell Carcinoma | 198 (82.5%) | |
Total-Non Clear Cell Carcinoma | 42 (17.5%) | |
Papillary | 22 (9.2%) | |
Chromophobe | 7 (2.9%) | |
PNET | 3 (1.2%) | |
Sarcomatoid | 5 (2.1%) | |
Unclassified | 5 (2.1%) | |
Average tumor size- | ||
RTS | 5.22 (SD 2.15) | |
PTS | 4.98 (SD 2.04) | |
Average difference between RTS and PTS- | 0.24 (SD 0.37) | |
Fuhrman grade | ||
I | 10 (4.2%) | |
II | 177 (73.8%) | |
III | 45 (18.8%) | |
IV | 8 (3.3%) | |
T stage- | Radiologic | Pathologic |
T1a | 100 (41.7%) | 121 (50.4%) |
T1b | 102 (42.5%) | 95 (39.6%) |
T2a | 30 (12.5%) | 17 (7.1%) |
T2b | 8 (3.3%) | 7 (2.9%) |
Stage change- | ||
Down-staged | 41 (17.1%) | |
Up-staged | 5 (2.1%) | |
Total | 46 (19.2%) |
Conclusions
There can be a discrepancy between radiologic size and pathologic tumor size in renal cell cancer which bears repercussions for its management. Message: Mangement of renal cell carcinoma should be carefully selected based on the tumor size diagnosed by CT scan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - NOTCH3 expression predicts poor survival in advanced esophageal squamous cell cancers
Presenter: Raja Pramanik
Session: Poster display session
Resources:
Abstract
144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
Presenter: Radka Obermannova
Session: Poster display session
Resources:
Abstract
145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
Presenter: Toshikazu Moriwaki
Session: Poster display session
Resources:
Abstract
146P - Anatomic versus non-anatomic resection for hepatocellular carcinoma: A meta-analysis of high-quality studies
Presenter: Bin Zhang
Session: Poster display session
Resources:
Abstract
147P - Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis
Presenter: Yingtai Chen
Session: Poster display session
Resources:
Abstract
148P - Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Presenter: Seunghwan Lee
Session: Poster display session
Resources:
Abstract
150P - A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Presenter: Yee Chao
Session: Poster display session
Resources:
Abstract
151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement
Presenter: Midie Xu
Session: Poster display session
Resources:
Abstract
152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma
Presenter: Chia-Lun Chang
Session: Poster display session
Resources:
Abstract
153P - Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis
Presenter: Dening Ma
Session: Poster display session
Resources:
Abstract